We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

LumiQuick Diagnostics

LumiQuick Diagnostics Inc. develops, manufactures and markets high quality point of care tests and other immunoassay ... read more Featured Products: More products

Download Mobile App





LumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio

By LabMedica International staff writers
Posted on 28 Jul 2026

LumiQuick Diagnostics, Inc. More...

(Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies bring products to the U.S. market. Building on the successful integration of AOXRE, LumiQuick is positioned to support oxidative stress research and specialty diagnostic technologies.

Beyond supplying products, the expanded offering includes original equipment manufacturer (OEM), private-label, and contract manufacturing services, along with strategic commercialization support for the United States. Together, these capabilities are designed to support partners from early development through market entry.

The service scope spans product development, design transfer, manufacturing scale‑up, and product assembly and packaging. Operational capabilities include reagent dispensing and packaging and custom diagnostic solutions across lateral flow immunoassays, rapid diagnostic tests, and ELISA development and manufacturing. 

The company's expertise also includes recombinant proteins, antibodies, biomarker assays, and reagent formulation, providing a single‑source pathway from concept through commercialization. Regulatory services include U.S. Food and Drug Administration (FDA) 510(k) submission support.

LumiQuick is seeking collaborations with biotechnology companies, diagnostic developers, research organizations, and international manufacturers aiming to establish or expand their U.S. presence with an experienced commercial and manufacturing partner. The team will be available at the ADLM Clinical Lab Expo 2026, Booth #1156, to discuss the expanding AOXRE portfolio, new product innovations, OEM and private‑label options, contract manufacturing, FDA 510(k) support, and commercialization partnerships.

The initiative underscores a commitment to advancing oxidative stress research and specialty diagnostic technologies through continued product innovation, expanded manufacturing capabilities, and strategic industry partnerships.

“Our goal is to become more than a manufacturer,” said Talita Franco, Business Development & Marketing Director at LumiQuick Diagnostics. “We are committed to helping innovative companies transform scientific discoveries into commercially successful products by combining technical expertise, manufacturing excellence, regulatory guidance, and market development support.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Thyroid Test
Anti-Thyroid EIA Test
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.